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Introduction
Parathyroid hormone (PTH) is secreted in the human 
body by the chief cells of the parathyroid glands. The 
bioactive, circulating form of PTH contains 84 amino 
acids and is formed from prohormone 115-amino acid 
sequence (preproPTH) by a cleavage process [1, 2]. PTH 
is mainly responsible for the regulation of extracellular 
calcium and phosphate concentrations. PTH causes 
an increase in plasma calcium concentration and a de-
crease in plasma phosphate concentration [1, 2]. It mo-
bilizes calcium and phosphate from the bone, decreases 
calcium excretion, and increases phosphate excretion by 
the kidneys, and finally, by stimulating the formation 
of 1,25 dihydroxyvitamin D3 in the kidneys, increases 
the intestinal absorption of calcium and phosphate. 
Extracellular ionized calcium is the main regulator of 
PTH excretion from the parathyroid glands. Decreased 
levels of ionized calcium stimulate excretion, and in-
creased levels inhibit it. The maximal stimulation of 
PTH excretion occurs when the plasma level of ionized 
calcium reaches 0.5 mmol/L or less. The maximal inhibi-
tion of PTH excretion occurs at an ionized calcium con-
centration of 2 mmol/L or more. The renally excreted, 
active form of vitamin D, namely 1,25 dihydroxyvitamin 
D3, inhibits PTH gene transcription and parathyroid cell 
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Introduction: Elevated serum parathormone (PTH) levels have been observed in acute kidney injury and are related to calcium-phosphate 
metabolism disturbance, decreased renal production of 1,25 dihydroxyvitamin D3, impaired renal PTH excretion, and other renal-inde-
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therapies (CRRT) in an intensive care setting. The primary objective of this study was to investigate trends in PTH serum levels in critically 
ill patients with multiorgan failure undergoing CRRT, by performing periodic PTH measurements in the acute phase of critical illness.
Material and methods: This was a single-centre, prospective, observational study conducted in an mixed, university-affiliated intensive 
care unit. Critically ill patients who fulfilled all of the following criteria were included: respiratory failure; circulatory failure; acute kidney 
injury treated by CRRT; and sequential organ failure assessment score (SOFA score) of 5 or more. Patients who met any of the following 
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plasma level > 1.35 mmol/L); parathyroid gland disease; end-stage renal disease; patients undergoing therapeutic plasma exchange or 
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SOFA score, and PTH levels were observed. A statistical test indicated that serum concentrations of PTH were significantly higher in the 
de novo sepsis group (p < 0.05).
Conclusions: The PTH serum concentration decreases during the course of CRRT in the majority of patients. When the course of the 
disease starts to be complicated by sepsis, PTH serum levels then remain high. A probable reason for this is the existence of the inflam-
matory state triggered by sepsis. (Endokrynol Pol 2021; 72 (4): 329–335)
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assess whether factors not associated directly with acute 
kidney injury, like disease severity, admission diagnosis, 
vitamin D status, age, and course of critical illness, can 
influence the PTH kinetic profile. We hypothesize that 
PTH serum concentrations normally decrease during 
the course of CRRT in critically ill patients.
Material and methods 
This was a prospective observational study conducted from May 
2019 to October 2020 in a single 11-bed, mixed, university-affiliated 
intensive care unit (ICU). Written informed consent was obtained 
from the patients’ relatives. The study was approved by the Region-
al Ethics Committee in Opole, Poland (protocol number: 278/2019; 
date of approval: 07/03/2019), registered before the recruitment of 
participants (clinicaltrials.gov; Identifier: NCT03873675) and car-
ried out according to the principles of the Declaration of Helsinki. 
Consecutive patients undergoing CRRT were evaluated for par-
ticipation in the study. Critically ill patients were included who 
fulfilled all of the following criteria: (1) respiratory failure; (2) 
circulatory failure; (3) acute kidney injury treated by continuous 
veno-venous hemodiafiltration (CVVHDF), which was started no 
later than 48 hours after admission to the ICU; and (4) a sequential 
organ failure assessment score (SOFA score) of five or more. We 
defined respiratory failure as a condition with clinical indications 
for invasive mechanical ventilation, and circulatory failure as 
a need for inotrope or/and vasopressor therapy. Indications for 
CRRT were based upon the KDIGO Clinical Practice Guidelines 
for Acute Kidney Injury document [16]. CVVHDF was performed 
using regional citrate anticoagulation, Prismaflex system and ST150 
set (Prismaflex, Gambro Lundia AB, Lund, Sweden) with polyac-
rylonitrile membrane (AN69). Continuous intravenous ionized 
calcium supplementation was performed using an external infu-
sion pump based on a dedicated citrate anticoagulation algorithm 
and kept within normal values during CRRT (hospital laboratory 
reference values: 1.15–1.33 mmol/L). Phosphate serum levels were 
monitored and supplemented as needed during patients’ stay in 
the intensive care unit (the standard of care in our institution) and 
also kept within normal values during CRRT (hospital laboratory 
reference values: 2.5–4.5 mg/dL).
Patients who met any of the following criteria were excluded: 
acute liver failure; hypercalcaemia at admission (total calcium 
serum level > 10.6 mg/dL; total ionized calcium plasma level > 
1.35 mmol/L); parathyroid gland disease; end-stage renal disease; 
patients undergoing therapeutic plasma exchange or extracorporeal 
membrane oxygenation (ECMO) procedures; aged under 18 years; 
pregnant; and those with life expectancy after admission to the 
intensive care unit anticipated to be less than 72 hours as assessed 
by the investigator.
The intact PTH was measured. Blood samples were taken from 
an arterial line or central venous line, or by direct peripheral ve-
nous or arterial puncture, and were collected in ethylenediamine 
tetra-acetic acid (EDTA) tubes. Blood samples were protected from 
exposure to light, transported to the hospital laboratory within 
30 minutes, centrifuged at 3500 rpm for 10 minutes, and processed 
by laboratory technicians. The PTH serum level was measured us-
ing an electrochemiluminescence ECLIA binding assay on Cobas 
e411 or Cobas 6000 immunoassay analysers (Roche Diagnostics 
GmbH, Mannheim, Germany). The PTH reference values were set 
between 14.9 and 56.9 pg/mL.
Consecutive patients admitted to the ICU were assessed in terms 
of study participation (inclusion and exclusion criteria) by the 
study investigator. In the majority of patients, the first PTH serum 
level was measured at the time of admission to the ICU. The first 
serum PTH level was measured before the initiation of CRRT. The 
next set of PTH serum levels was taken in 12-hour time intervals 
(twice daily, at 6 a.m. and 6 p.m.). The minimum necessary number 
of PTH measurements was six and the maximum was eight. The 
levels of 25 hydroxyvitamin D3, albumin and protein, coagulation 
proliferation. There are many additional modulators of 
PTH secretion in the human body such as lithium, trans-
forming growth factor alfa, prostaglandins, inorganic 
phosphate, and fibroblast growth factor 23 (FGF-23) 
[1, 2]. FGF-23 inhibits renal phosphate reabsorption in 
the proximal renal tubules and reduces the circulatory 
level of 1,25 dihydroxyvitamin D3.
Besides the classic mechanisms, serum PTH concen-
trations can change in a non-serum calcium-dependent 
manner. PTH serum levels can increase in proportion 
to the severity of illness, infection, and inflammatory 
response [3]. It has been observed that significantly in-
creased serum PTH levels correlate with the severity of 
critical illness, length of hospital stay, and mortality [4, 
5]. PTH may also be treated as a marker of hypoperfu-
sion, and elevated PTH serum levels reflect the risk of 
mortality in critically ill trauma patients [6]. However, 
it is unclear whether elevated PTH serum levels are 
isolated phenomena or reflect the severe perturbation 
of the 25 hydroxyvitamin D3-PTH-serum calcium axis 
in the course of critical illness [7,8]. Generally, the role 
of PTH in the pathophysiology of critical illness is 
under-researched.
Elevated serum PTH levels have also been observed 
in acute kidney injury. Elevated PTH serum levels are 
related to calcium-phosphate metabolism disturbance, 
decreased renal production of 1,25 dihydroxyvitamin 
D3, impaired or completely inhibited renal PTH excre-
tion, and other renal-independent factors mentioned 
above [10–12]. Acute kidney injury is a commonly ob-
served complication in intensive care, with mortality 
rates reaching 70% and the need for renal replacement 
therapy in up to 10% of cases [13]. Continuous renal 
replacement therapy (CRRT) is the standard of care in 
many intensive care units, especially when haemody-
namic instability predominates the course of critical 
illness. Typical indications for CRRT in an intensive 
care setting are as follows: persistent/progressive acute 
kidney injury, volume overload, metabolic acidosis, 
electrolyte abnormalities, and uraemia [13]. In chronic 
kidney disease (end-stage renal disease) haemodialy-
sis patients, changes in PTH serum levels depend on 
calcium status and the adsorptive properties of dialysis 
membranes [14]. Moreover, the composition of dialysis 
solutions influences changes of PTH serum concentra-
tions during haemodialysis and haemodiafiltration 
procedures [15]. To date, there are no data regarding 
PTH kinetics in critically ill patients with multiorgan 
failure undergoing CRRT in an intensive care setting.
The primary objective of this study was to investi-
gate trends in PTH serum levels in critically ill patients 
with multiorgan failure undergoing CRRT, by perform-
ing periodic serum PTH measurements in the acute 
phase of critical illness. The second objective was to 
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tests, and bilirubin were measured at admission to the ICU. Ionized 
calcium and postfilter calcium were measured four times per day 
according to the CRRT protocol. Additional laboratory data such as 
blood count, serum creatinine, urea, phosphate, total calcium, and 
magnesium were measured once a day during the study period.
All demographic data (date, name, hospital documentation num-
ber, sex, age, diagnosis at admission, comorbidities, admission 
SOFA score, and additional laboratory tests) were recorded in 
the hospital’s electronic database. After the recruitment process, 
patient data were extracted from the electronic database, the pa-
tient’s identification was blinded, and the data were transferred to 
a statistician for analysis.
Statistical methods
The quantitative variables were characterized by the arithmetic 
mean of standard deviation or median or max/min (range). The 
qualitative variables were presented using counts and percent-
ages. In order to check whether a quantitative variable derived 
from a population with normal distribution, the W Shapiro-Wilk 
test was used. To prove the hypotheses on homogeneity of vari-
ances, the Levene (Brown-Forsythe) test was used. The statistical 
significance of differences between two groups was processed 
with Student’s t-test or Mann-Whitney U test. The significance of 
difference between more than two groups was assessed with the 
F test (ANOVA) or Kruskal-Wallis test. In the case of statistically 
significant differences between two groups, post hoc tests were 
used (Tukey test for F or Dunn for Kruskal-Wallis). In the case of 
two paired variables, model Student’s t-test or Wilcoxon signed-
rank test was used. The significance of difference between more 
than two variables in the paired variables model was checked by 
analysis of variance with repeated measurements or by the Fried-
man test. Chi-squared tests for independence were used for quali-
tative variables. In order to determine the dependence, strength, 
and direction between variables, correlation analysis was used by 
determining the Pearson or Spearman’s correlation coefficients. 
In all the calculations a statistical significance level of p = 0.05 was 
used. The statistical analyses were performed using STATISTICA 
software v. 12.0 (StatSoft Inc., 2014). 
Results
A total of 79 patients were evaluated for participation 
in the study. Forty-nine patients were excluded. The 
reasons for exclusion were as follows: no respiratory 
failure (9 patients), end-stage renal disease (6 patients), 
less than 6 PTH measurements performed (14 patients), 
CRRT started > 48 hours after admission to the intensive 
care unit (8 patients), ECMO (4 patients), anticipated life 
expectancy after admission to the intensive care unit of 
less than 72 hours (4 patients), and others (4 patients). 
Finally, 30 patients met the inclusion criteria and were 
included in the study. The baseline demographics for 
the study group are shown in Table 1 and 2. All patients 
fulfilled the KDIGO criteria of stage 3 acute kidney in-
jury. The prescribed CVVHDF dose (effluent flow rate) 
was set between 30 and 42 mL/kg/h. Other CRRT pa-
rameters were as follows: blood flow 120–160 mL/min; 
dialysate flow 1000–1500 mL/h; replacement fluid flow 
600–1500 mL/h; and citrate supply 2.6–3.6 mmol/L. The 
net fluid loss was set between 0 and 200 mL/h. In the 
majority of patients, the ratio of diffusion to convection 
was set between 1:1 and 1:0.5.
The median serum concentration of PTH (first 
measurement) was 180.5 pg/mL (5.0–668.0), the 2nd 
measurement was 166.5 pg/mL (15.0–347.0), the 3rd mea-
surement was 71.0 pg/mL (16.0–182.0), the 4th measure-
ment was 55.5 pg/mL (16.0–196.0), the 5th measurement 
was 57.5 pg/mL (15.0–127.0), the 6th measurement was 
64.5 pg/mL (15.0–205.0), the 7th measurement was 57.5 
pg/mL (15.0–296.0), and the 8th measurement was 62.0 
pg/mL (17.0–199.0). A summary of the statistical analy-
sis of PTH serum concentration is shown in Table 3, 
the change in average values of PTH in Figure 1, and 
the change in medians in Figure 2. The statistical test 
(Friedman ANOVA) showed a statistically significant 
change in PTH over time (p = 0.0001). The post-hoc 
test showed a statistically significant decrease in PTH: 
measurements 5–8 relative to measurement 1, and 
measurements 4–8 relative to measurement 2 (p < 0.05). 
No statistically significant changes were found for the 
remaining comparisons (p > 0.05).
Seventeen patients in the study group (56.7%) 
were discharged from the ICU, and 13 patients (43.3%) 
Table 1. Descriptive statistics (age, gender, BMI, serum 
concentrations of 25 hydroxyvitamin D3, and the SOFA score)
Study group (n = 30)
Age (years)





Mean (SD) 25.9 (3.8)
25 hydroxyvitamin D3




SD — standard deviation; BMI — body mass index; SOFA — sequential organ 
failure assessment score
Table 2. Descriptive statistics: diagnosis at admission
Diagnosis Study group (n = 30)
Septic shock 11 (36.7%)
Sudden cardiac arrest 8 (26.7%)
Multiple organ dysfunction 8 (26.7%)
Acute pancreatitis 1 (3.3%)
Haemorrhagic shock 1 (3.3%)
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died. No significant correlations between outcome 
and PTH values were observed. A total of 21 patients 
(70%) had severe 25 hydroxyvitamin D3 deficiency at 
admission to the ICU (25 hydroxyvitamin D3 serum 
level < 12.5 ng/mL). No significant correlations between 
25 hydroxyvitamin D3 deficiency and PTH levels were 
observed. Also, no significant correlations between 
age, admission diagnosis, SOFA score, and PTH values 
were found. 
In 10 patients (33.3%), de novo sepsis or septic 
shock was diagnosed during the measurement period 
based on Surviving Sepsis Campaign criteria [17]. Ad-
ditionally, we noted elevated serum C-reactive protein 
(CRP) and procalcitonin levels in these patients (CRP 
47–728 mg/L; procalcitonin 0.6–400 ng/mL). Differ-
ent relations were observed in patients who became 
septic and patients who remained non-septic during 
the measurement period. A statistical test indicated 
that serum concentrations of PTH: 3–8 measurements 
were significantly higher in the de novo sepsis group 
(p < 0.05) compared to the non-sepsis group. There 
were no significant differences between measure-
ments of serum PTH concentrations in the de novo 
sepsis group (p = 0.7045). The statistical test (Friedman 
ANOVA) showed a statistically significant change in 
PTH serum levels over time in the non-sepsis group 
(p = 0.0001). The post-hoc test showed a statistically 
significant decrease in PTH serum concentrations: 
measurements 4–8 relative to measurement 1 and 2 
(p < 0.05). No statistically significant changes were 
found for the remaining comparisons of measurements 
(p > 0.05). Comparative analysis of mean PTH serum 
concentrations in the de novo sepsis and non-sepsis 
groups are shown in Figure 3 and Table 4.
Discussion
We found a general trend in serum PTH concentra-
tions in critically ill patients with multi-organ failure 
Table 3. Summary statistical analysis of parathormone 
(PTH) serum concentrations PTH reference values: 14.9–56.9 
[pg/mL]



















































 Mean ± standard error
 Mean ± 1.96 standard error
Figure 1. The change in parathormone (PTH) serum levels: 





























Figure 2. The change in parathormone (PTH) serum levels; 
medians (*, *p < 0.05); PTH reference values: 14.9–56.9 
[pg/mL]
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undergoing CRRT. In the majority of patients (25; 
83.3%), we noted significantly elevated serum PTH 
levels before starting the renal replacement procedure. 
This can mainly be attributed to the acute kidney injury 
and inhibited renal PTH elimination. The subsequent 
and gradual decrease in serum PTH concentrations in 
the course of CRRT can be explained by the washout 
process on the haemofilter. PTH has a molecular mass 
of 9500 daltons (Da). In the CVVHDF mode of CRRT 
used in all patients included in the study, there were 
two mechanisms responsible for the elimination pro-
cess of particles, namely diffusion and convection. In 
the majority of our patients the ratio of diffusion to 
convection was set between 1:1 and 1:0.5. During the 
diffusion process, only small molecules can be removed. 
However, in the case of convection molecules with 
a greater molecular mass of up to 30,000 Da can be easily 
eliminated [18]. We assume that the decrease in PTH 
serum concentration in the majority of our patients was 
solely attributable to the convection process. Addition-
ally, the PTH elimination process could be related to 
the adsorptive properties of the AN69 membrane. We 
assume that the accumulation of PTH in acute kidney 
injury before the beginning of CRRT is proportional to 
the period of disrupted kidney function, and inversely 
Figure 3. Comparative analysis of mean values of plasma 
concentration of parathormone (PTH) in sepsis and non-


























a ba        b
Table 4. Comparative analysis of mean values of parathormone (PTH) serum concentrations in sepsis and non-sepsis 
groups PTH reference values: 14.9–56.9 [pg/mL]
Sepsis (n = 10) Non-sepsis (n = 20) p value
PTH — 1 0.5526
Median 173.0 184.5
Range 20.0–306.0 5.0–668.0
PTH — 2 0.5500
Median 186.5 152.0
Range 86.0–229.0 15.0–347.0
PTH — 3 0.0002
Median 148.5 49.5
Range 28.0–182.0 16.0–139.0
PTH — 4 0.0019
Median 135.5 48.5
Range 43.0–196.0 16.0–88.0
PTH — 5 0.0164
Median 87.5 50.0
Range 30.0–127.0 15.0–100.0
PTH — 6 0.0107
Median 119.5 54.5
Range 24.0–189.0 15.0–205.0
PTH — 7 0.0008
Median 125.0 44.5
Range 58.0–296.0 15.0–127.0
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proportional to the degree of residual kidney function. 
In 10 patients (33.3%) significantly elevated serum PTH 
levels were observed, which remained relatively high 
during subsequent measurements. The PTH washout 
during CRRT was preserved in septic patients, but the 
PTH production and excretion process was probably 
stimulated by inflammation. We can assume that trends 
in PTH serum concentrations can be used as another 
marker of inflammation. Further studies are needed to 
explore this phenomenon.
In a prospective observational cohort study, Greulich 
et al. found that patients with sepsis have high levels of 
PTH and lower blood levels of 25 hydroxyvitamin D3. 
The authors linked this phenomenon to a susceptibility 
to developing sepsis [19]. Severe 25 hydroxyvitamin D3 
deficiency is common in critically ill patients. The serum 
concentrations of 25 hydroxyvitamin D3 are low and 
stable during the therapeutic process in the ICU, also in 
patients undergoing CRRT [8, 20]. We assume that sharp 
rises in PTH serum concentrations are independent of 
vitamin D status and the vitamin D-PTH-calcium axis in 
the human body, but instead contribute to the inflamma-
tory cascade during sepsis. Carlstedt et al. observed that 
elevated levels of serum PTH are common in critically 
ill patients and the extent of the increase is related to 
the severity of disease and mortality. This phenomenon 
was observed in a broad mixture of ICU patients and 
especially in two specific disease groups, namely septic 
patients and those subjected to major surgery. The au-
thors linked this with a systemic inflammatory response 
but concluded that the direct influence of inflammatory 
mediators on the calcium responsiveness of the PTH 
release is unknown. The authors also hypothesized that 
catecholamines could stimulate PTH secretion because 
beta-adrenergic receptors are present on parathyroid 
cell surfaces [21]. In a prospective observational study, 
Yang et al. found that elevated PTH serum levels in 
post cardiac surgery patients with a clinical diagnosis 
of acute kidney injury were marginally associated with 
poor outcomes [22]. In a prospective cross-sectional 
study, Ardehali et al. observed that in neurosurgical ICU 
patients with increasing PTH serum levels, the risk of 
stay in the ICU increased by 2%. The authors confirmed 
that PTH could be regarded as a marker of inflammation 
and disease severity [23]. In a prospective observational 
study, Fligor et al. highlighted the potential utility of 
PTH as a marker of hypoperfusion in trauma shock 
patients. The authors concluded that sequentially esti-
mated serum PTH levels could be a useful index of effec-
tive resuscitation in shock [6].Based on the results of our 
study and the review of the literature, we hypothesize 
that the most probable reason for prolonged elevated 
serum PTH concentrations in critically ill patients is the 
inflammatory state in the course of critical illness. We do 
not know if there is a relationship between the extent of 
PTH serum elevation and the intensity of sepsis; hence, 
further studies are merited. Initially elevated serum PTH 
levels are common in multiorgan failure with the coex-
istence of acute kidney injury; however, CRRT tends to 
normalize these levels. When sepsis and inflammation 
begin to predominate, the decline of previously elevated 
serum PTH levels is impaired.
Our study has several limitations. The first is the 
small number of patients included. However, this is 
the first study aimed at estimating the PTH serum con-
centration kinetic profile during CRRT. A larger cohort 
would be more accurate to evaluate above-mentioned 
relations. The second limitation is that we did not mea-
sure the broad spectrum of inflammatory markers in 
our study. The diagnosis of sepsis was based solely on 
clinical symptoms as well as commonly used laboratory 
markers such as C-reactive protein, procalcitonin, and 
leukocytosis. PTH stimulates interleukin-6 production 
by osteoblasts and the liver, and this specific marker of 
inflammation would be more effective in the evaluation 
of the intensity of inflammation [24, 25]. The third is 
that we did not measure PTH concentration in the ef-
fluent, which would potentially show the range of PTH 
washout during CRRT. However, the PTH elimination 
process is probably related to the adsorptive properties 
of AN69 membrane as well. Finally, the study popula-
tion was rather heterogeneous. However, our patients 
represent a typical, broad intensive care milieu, and 
substantially reflect typical intensive care scenarios.
Conclusions
Critically ill patients with acute kidney injury un-
dergoing continuous renal replacement therapies 
initially have elevated serum PTH concentrations. We 
found that the PTH serum concentration decreases 
rapidly during the course of CRRT in the majority of 
patients. When the course of the disease starts to be 
complicated by sepsis, PTH serum levels then remain 
high. The most probable reason for this phenomenon 
could be the existence of the inflammatory state trig-
gered by sepsis.
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